AKT1 and colorectal adenocarcinoma: The Akt-specific inhibitor LY294005 increased the efficacy of docetaxel, did not affect the efficacy of 6-thioguanine, and decreased the efficacy of cisplatin, lipoplatin, oxaliplatin, and lipoxal in human colorectal adenocarcinoma sublines, suggesting a novel property of Akt in aggravating drug sensitivity [31].